Gordian Biotechnology is introducing a method of screening hundreds of gene therapies simultaneously in an individual animal model – its co-founders explain
April 25, 2024 •
Gordian Biotechnology
About Gordian Biotechnology
Founded in 2018 and headquartered in San Francisco, Gordian is an in vivo drug discovery and development company whose mission is to cure age-related diseases. Named for solving intractable problems by changing the rules, the company has developed an innovative in vivo screening platform that tests thousands of gene therapies and predicts clinical outcomes with unprecedented accuracy and efficiency. The Gordian Platform comprises three proprietary components working in concert to drive predictive ability. Mosaic Screening is the Gordian method of pooled in vivo screening, Patient Avatars are animals most representative of humans, and Pythia is an analysis methodology that combines Gordian screening data with existing human data and uses machine learning to maximize predictive power. The company is funded by world-renowned investors including The Longevity Fund, Athos Service GmbH, Gigafund, Founders Fund, and former Novartis CEO Thomas Ebeling. Gordian: Creating Time.
